600511 国药股份
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入39,381,3013.56%50,597,45049,696,04645,498,58446,468,603
减:营业总成本37,808,1884.12%48,403,88747,194,08943,218,51344,351,267
    其中:营业成本36,882,4674.31%47,002,22645,704,77641,676,31842,837,500
               财务费用(16,578)-77.50%(68,030)(126,127)(28,840)(18,342)
               资产减值损失(9,922)45.26%(1,066)389(5,140)(17,588)
公允价值变动收益----(18,202)10,817----
投资收益440,99139.37%514,166358,952291,622283,351
    其中:对联营企业和合营企业的投资收益411,06228.37%515,180456,539380,800380,222
营业利润1,945,536-2.20%2,677,4222,944,3582,694,9232,447,274
利润总额1,933,742-1.63%2,653,6122,930,8902,687,8862,444,806
减:所得税费用377,848-3.34%523,832596,420559,181516,303
净利润1,555,894-1.21%2,129,7812,334,4712,128,7051,928,503
减:非控股权益63,629-32.06%129,654188,472164,648174,418
股东净利润1,492,2650.74%2,000,1272,145,9991,964,0581,754,084

市场价值指针
每股收益 (元) *1.9780.74%2.6512.8442.6032.325
每股派息 (元) *----0.8000.8540.7820.700
每股净资产 (元) *23.9138.64%22.70120.90918.84016.938
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容